Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.
2.

Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.

Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, Lau KK, Chan KH, Lau CP, Lip GY, Leung GK, Tse HF, Siu CW.

Stroke. 2015 Jan;46(1):23-30. doi: 10.1161/STROKEAHA.114.006476. Epub 2014 Nov 18.

PMID:
25406148
3.

Stroke and bleeding risk in atrial fibrillation.

Senoo K, Lane D, Lip GY.

Korean Circ J. 2014 Sep;44(5):281-90. doi: 10.4070/kcj.2014.44.5.281. Review.

4.

Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.

Scott KA, Amirehsani KA.

J Am Assoc Nurse Pract. 2015 Apr;27(4):190-6. doi: 10.1002/2327-6924.12161. Epub 2014 Jul 25.

PMID:
25066647
5.

Dabigatran etexilate in atrial fibrillation.

Vora A.

J Assoc Physicians India. 2013 Dec;61(12):900-2. Review.

PMID:
24968547
6.

Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.

Ezekowitz MD, Spahr J, Ghosh P, Corelli K.

J Interv Card Electrophysiol. 2014 Sep;40(3):261-8. doi: 10.1007/s10840-014-9893-z. Epub 2014 Jun 1.

PMID:
24880227
7.

Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.

Marcucci M, Lip GY, Nieuwlaat R, Pisters R, Crijns HJ, Iorio A.

Am J Med. 2014 Oct;127(10):979-986.e2. doi: 10.1016/j.amjmed.2014.05.003. Epub 2014 May 13.

PMID:
24838192
8.

Lower-dose warfarin delays renal progression and prolongs patient survival in patients with stage 3 - 5 chronic kidney disease and nonvalvular atrial fibrillation: a 12-year follow-up study.

Chiu PF, Huang CH, Liou HH, Wu CL, Chang C, Chang CC, Chang HR.

Int J Clin Pharmacol Ther. 2014 Jun;52(6):504-8. doi: 10.5414/CP202053.

PMID:
24755133
9.

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.

Haas S, Bode C, Norrving B, Turpie AG.

Vasc Health Risk Manag. 2014 Mar 10;10:101-14. doi: 10.2147/VHRM.S55246. eCollection 2014. Review.

10.

Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T.

JAMA. 2014 Mar 5;311(9):919-28. doi: 10.1001/jama.2014.1334.

PMID:
24595776
11.

Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.

Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, Swarup V, Chalhoub F, Atkins D, Bommana S, Verma A, Sanchez JE, Burkhardt JD, Barrett CD, Baheiry S, Ruskin J, Reddy V, Natale A.

J Am Coll Cardiol. 2014 Mar 18;63(10):982-8. doi: 10.1016/j.jacc.2013.11.039. Epub 2014 Jan 8.

12.

Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.

Albert NM.

Heart Lung. 2014 Jan-Feb;43(1):48-59. doi: 10.1016/j.hrtlng.2013.10.014. Epub 2013 Nov 11. Review.

PMID:
24373340
13.

Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.

J Am Heart Assoc. 2013 Nov 25;2(6):e000535. doi: 10.1161/JAHA.113.000535.

14.

Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF.

Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators.

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1142-7. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.001. Epub 2013 Nov 1.

PMID:
24189454
15.
16.

Stroke Prevention in Atrial Fibrillation [Internet].

Lopes RD, Crowley MJ, Shah BR, Melloni C, Wood KA, Chatterjee R, Povsic TJ, Dupre ME, Kong DF, de Barros e Silva PGM, dos Santos MHH, Armaganijan LV, Katz M, Kosinski A, McBroom AJ, Chobot MM, Gray R, Sanders GD.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Aug.

17.

Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.

Lip GY, Lane DA, Buller H, Apostolakis S.

Chest. 2013 Dec;144(6):1839-47. doi: 10.1378/chest.13-1635.

PMID:
24009027
18.

Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage.

Khalid F, Qureshi W, Qureshi S, Alirhayim Z, Garikapati K, Patsias I.

Ren Fail. 2013 Oct;35(9):1228-35. doi: 10.3109/0886022X.2013.819766. Epub 2013 Aug 1.

PMID:
23902367
19.

[ANMCO statement on prevention of thromboembolism in atrial fibrillation and role of the new oral anticoagulants].

Colonna P, Abrignani MG, Colivicchi F, Verdecchia P, Alunni G, Bongo AS, Ceravolo R, Oliva F, Rakar S, Riccio C, Scherillo M, Valle R, Bovenzi F; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO).

G Ital Cardiol (Rome). 2013 Apr;14(4):295-322. doi: 10.1714/1257.13889. Italian.

PMID:
23567775
20.

Clinical update on the management of atrial fibrillation.

Danelich IM, Reed BN, Hollis IB, Cook AM, Rodgers JE.

Pharmacotherapy. 2013 Apr;33(4):422-46. doi: 10.1002/phar.1217. Review.

PMID:
23553811
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk